Q4 2025 Medexus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Medexus Pharmaceuticals Inc (MEDXF) achieved $0.6 million in product-level revenue for GRAFAPEX in fiscal Q4 '25, with preliminary estimates indicating over $2.5 million in fiscal Q1 '26.
- The company expects GRAFAPEX to be accretive to quarterly operating cash flows by fiscal Q4 '26, with an anticipated annual product-level adjusted gross margin of approximately 80%.
- Medexus Pharmaceuticals Inc (MEDXF) reported record adjusted EBITDA of $20.2 million and record net income of $2.2 million for fiscal year '25, demonstrating strong financial discipline.
- The launch of GRAFAPEX in the United States has been met with a positive market response, with 34 of 180 transplant centers already ordering the product.
- The company has successfully negotiated favorable payment terms for the $15 million regulatory milestone under the GRAFAPEX agreement, supporting its growth strategy.
- Fiscal Q4 net revenue decreased to $24.8 million from $26 million in the same period last year, primarily due to investments in GRAFAPEX commercialization.
- Adjusted EBITDA for fiscal Q4 '25 decreased to $2.3 million from $4.4 million in the same period last year, impacted by $2.7 million in GRAFAPEX-related investments.
- Net income for fiscal Q4 '25 was negative $0.6 million, a decline from positive $0.8 million in the same period last year.
- The company faces generic competition for Rupall in Canada, which could impact its market share and revenue.
- Medexus Pharmaceuticals Inc (MEDXF) reported a decrease in fiscal year '25 net revenue to $108.3 million from $113.1 million in fiscal '24, reflecting challenges in maintaining revenue growth.
Greetings. Welcome to the Medexus Pharmaceuticals fourth quarter and fiscal year-end 2025 conference call. (Operator Instructions)
Please note, this conference is being recorded. I will now turn the conference over to your host, Victoria Rutherford, Investor Relations of Medexus.
You may begin.
Thank you, and good morning, everyone. Welcome to the Medexus Pharmaceuticals fourth quarter and fiscal year 2025 earnings call. On the call this morning are Ken d'Entremont, Chief Executive Officer; and Brendon Buschman, Chief Financial Officer. If you have any questions after the conference call or would like further information about the company, please contact Adelaide Capital at 480-625-5772. I would like to remind everyone that this discussion will include forward-looking information as defined in Canadian securities laws that is based on certain assumptions that Medexus believes to be reasonable in the circumstances but is subject to risks and uncertainties.
Actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
